|
1
|
Lamanna E, Conde E, Mougel A, Bonnefoy J, Colaone F, Godon O, Hamdi S, Kamphuis JBJ, Drouet B, Serra V, Bruhns P, Reber LL. A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice. Allergy 2023. [PMID: 36799426 DOI: 10.1111/all.15680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 01/16/2023] [Accepted: 02/05/2023] [Indexed: 02/18/2023]
Affiliation(s)
- Emma Lamanna
- Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France.,Neovacs SA, Suresnes, France
| | - Eva Conde
- Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France.,Neovacs SA, Suresnes, France.,Sorbonne Université, College Doctoral, Paris, France
| | - Aurélie Mougel
- Neovacs SA, Suresnes, France.,Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| | | | | | - Ophélie Godon
- Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France
| | | | - Jasper B J Kamphuis
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| | | | | | - Pierre Bruhns
- Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France
| | - Laurent L Reber
- Neovacs SA, Suresnes, France.,Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France
| |
Collapse
|
|
2
|
Guilleminault L, Conde E, Reber LL. Pharmacological approaches to target type 2 cytokines in asthma. Pharmacol Ther 2022; 237:108167. [PMID: 35283171 DOI: 10.1016/j.pharmthera.2022.108167] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Revised: 02/17/2022] [Accepted: 03/07/2022] [Indexed: 02/06/2023]
Abstract
Asthma is the most common chronic lung disease, affecting more than 250 million people worldwide. The heterogeneity of asthma phenotypes represents a challenge for adequate assessment and treatment of the disease. However, approximately 50% of asthma patients present with chronic type 2 inflammation initiated by alarmins, such as IL-33 and thymic stromal lymphopoietin (TSLP), and driven by the TH2 interleukins IL-4, IL-5 and IL-13. These cytokines have therefore become important therapeutic targets in asthma. Here, we discuss current knowledge on the structure and functions of these cytokines in asthma. We review preclinical and clinical data obtained with monoclonal antibodies (mAbs) targeting these cytokines or their receptors, as well as novel strategies under development, including bispecific mAbs, designed ankyrin repeat proteins (DARPins), small molecule inhibitors and vaccines targeting type 2 cytokines.
Collapse
Affiliation(s)
- Laurent Guilleminault
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, 31024 Toulouse, France; Department of Respiratory Medicine, Toulouse University Hospital, Faculty of Medicine, Toulouse, France
| | - Eva Conde
- Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, F-75015 Paris, France; Sorbonne University, ED394, F-75005 Paris, France
| | - Laurent L Reber
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, 31024 Toulouse, France.
| |
Collapse
|